Takeda (China) International Trading Co. Ltd.

Takeda’s pipeline cull affected assets outside of oncology. Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday when the drugmaker axed (PDF) a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline. Under CEO Christophe Weber, Takeda has worked to establish itself as a leader in oncology. But, as the executive said on a quarterly results call with investors, the company has “had some wins ... [and] some setbacks.” The results brought news of more setbacks, with Takeda using the update to reveal it has dropped a clutch of cancer candidates led by modakafusp alfa. Formerly known as TAK-573, modakafusp alfa consists of two interferon alpha-2b molecules fused to an anti-CD38 monoclonal antibody. The idea was to activate innate and adaptive immune cells—while also directly stopping the proliferation of multiple myeloma cells—through targeted interferon signaling. Takeda began a phase 1/2a Darzalex combination trial one year ago, adding to the slate of studies run in support of the immunocytokine, but has now pulled the plug on the program. Andrew Plump, M.D., Ph.D., president of R&D at Takeda, explained the decision on the conference call with investors.  “This is a strategic decision based on a number of factors, including the existing data set, the rapidly evolving multiple myeloma treatment landscape and the long development timelines,” the R&D chief said.  Takeda pushed modakafusp alfa out of the door as part of a pipeline clear-out that also hit three phase 1 autologous CAR-T candidates. Two of the prospects, GPC3-targeted TAK-102 and mesothelin-directed TAK-103, were in development in solid tumors. The third asset, TAK-940, was a CD19-directed, Memorial Sloan Kettering Cancer Center-partnered program that used the 1XX domain to try to enhance efficacy. While Takeda axed a clutch of cancer candidates, Plump said the company “remains committed to oncology and will continue to develop therapies across hematologic and solid tumors.” The R&D chief highlighted the SUMO inhibitor subasumstat, a pair of STING agonists and two T-cell engagers from the Maverick Therapeutics acquisition as candidates to watch.  Plump also cited the appointment of PK Morrow, who joined Takeda from CRISPR Therapeutics last month, as a boost for the oncology unit. Morrow became head of the oncology therapeutic area unit at Takeda, having previously worked as chief medical officer of CRISPR, and held various roles at Amgen. Takeda’s pipeline cull also affected assets outside of oncology. The drugmaker removed three phase 2 drug candidates, namely the rare disease asset TAK-611—which flunked a trial last year—the Parkinson’s disease prospect TAK-071 and the depression molecule TAK-041. In phase 1, Takeda axed treatments for Alzheimer’s disease and nausea as well as a Zika vaccine candidate. Amid the changes, Takeda grew its R&D spend by 7.3%, although Chief Financial Officer Costa Saroukos said that “does reflect some phasing,” and the company is still aiming for a mid single digit increase over the full year. Saroukos made the comment on what looks set to be his last quarterly results conference call as CFO of Takeda.  Milano Furuta, president of Takeda’s Japan pharma business unit, is preparing to take over as CFO in April. Saroukos is leaving because “after 20 years working abroad, I’m ready to move back to Australia to be closer to my family,” the outgoing CFO told investors.

– EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study – Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating EXKIVITY’s Clinical Benefit and Durable Responses in EGFR Exon20 Insertion+ NSCLC – Results Demonstrated a Confirmed Overall Response Rate (ORR) of 28% and Median Duration of Response (DoR) of 15.8 Months per Independent Review Committee (IRC) OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. EXKIVITY has shown clinically meaningful and durable responses in patients with locally advanced or metastatic EGFR Exon20 insertion+ NSCLC and is now the first and only treatment available for this patient population in China. EXKIVITY, an oral tyrosine kinase inhibitor designed to target Exon20 insertions, was reviewed as part of the NMPA’s Breakthrough Therapy program. Full approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. “The approval of EXKIVITY in China for patients with locally advanced or metastatic EGFR Exon20 insertion+ NSCLC was only possible through dedicated collaboration and support from the NMPA and the Chinese government,” said Awny Farajallah, Head, Global Medical Affairs Oncology, Takeda. “Lung cancer is a devastating disease, and we know the discovery and delivery of precision medicines like EXKIVITY to target cancer types that are hard-to-treat have the potential to improve patient outcomes. We are thrilled to introduce EXKIVITY in China as the second lung cancer therapy from Takeda and remain committed to research and development to meet the needs of this patient community.” Lung cancer is the most commonly diagnosed cancer in China, and NSCLC accounts for approximately 85% of all lung cancer cases in the country.1 Of those patients diagnosed with EGFR-mutated NSCLC in China, up to 10% harbor Exon20 insertions.2-7 Despite this prevalence, patients in China have lacked a targeted treatment option designed to address cancers driven by these mutations. “Since the discovery of EGFR mutations nearly twenty years ago, patients with Exon20 insertions have been waiting for a targeted therapy to treat their disease,” said Sean Shan, President of Takeda China. “The approval of EXKIVITY in China is a remarkable breakthrough, demonstrating the strong commitment of the Chinese government to encourage and accelerate the introduction of innovative therapies. EXKIVITY offers a targeted, oral therapy to a population that has been historically underserved, and this approval brings us one step closer to defeating this complex and heterogeneous disease for patients in this region.” This approval is based on the results from the platinum-pretreated population in the Phase 1/2 trial of EXKIVITY, which consisted of 114 patients with EGFR Exon20 insertion+ NSCLC who received prior platinum-based therapy and were treated at the 160 mg dose. Results demonstrated a confirmed ORR of 28% per IRC as well as a median DoR of 15.8 months per IRC, a median overall survival (OS) of 20.2 months and a median progression-free survival (PFS) of 7.3 months per IRC. The most common treatment-related adverse reactions (TRAEs) were diarrhea (92%), rash (46%), paronychia (38%) and decreased appetite (37%). About EXKIVITY (mobocertinib) EXKIVITY is a first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations. EXKIVITY is currently approved in the United States, Great Britain, Switzerland, South Korea, Australia and China for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. For more information about EXKIVITY, visit . For the Prescribing Information, including the Boxed Warning, please visit . About EGFR Exon20 Insertion+ NSCLC Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 2.2 million new cases of lung cancer diagnosed each year worldwide, according to the World Health Organization.9, 10 Patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ NSCLC make up approximately 1-2% of patients with NSCLC, and the disease is more common in Asian populations compared to Western populations.2-6 This disease carries a worse prognosis than other EGFR mutations, as EGFR TKIs – which do not specifically target EGFR Exon20 insertions – and chemotherapy provide limited benefit for these patients. Takeda is committed to continuing research and development to meet the needs of the lung cancer community through the discovery and delivery of transformative medicines. EXKIVITY IMPORTANT SAFETY INFORMATION QTc Interval Prolongation Heart rate-corrected QT (QTc) interval prolongation, including resultant life-threatening arrhythmias, such as Torsades de Pointes, occurred in patients treated with mobocertinib. A concentration-dependent QTc interval prolongation of approximately 12.7 msec (90% CI: 8.69, 16.8) was observed at the steady-state Cmax following 160 mg daily doses based on an analysis of data from 194 patients with advanced solid malignances. Clinical trials of mobocertinib did not enroll patients with baseline QTc greater than 470 msec. Assess QTc and electrolytes at baseline and correct abnormalities in sodium, potassium, calcium, and magnesium prior to initiating mobocertinib. Monitor QTc and electrolytes periodically during treatment. Increase monitoring frequency in patients with risk factors for QTc prolongation, such as in patients with congenital long QTc syndrome, heart disease, electrolyte abnormalities, or those who are taking medicinal products known to prolong the QTc interval. Avoid concomitant use of medicinal products which are known to prolong the QTc interval. Avoid concomitant use of strong or moderate CYP3A inhibitors with mobocertinib, which may further prolong the QTc interval. Permanently discontinue mobocertinib in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia. Interstitial Lung Disease/Pneumonitis Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis have occurred in patients treated with mobocertinib. Withhold mobocertinib for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation and diagnosis confirmation. Permanently discontinue mobocertinib if ILD/pneumonitis is confirmed. Cardiac Toxicity Cardiac failure (including congestive cardiac failure, decreased ejection fraction, and cardiomyopathy) has occurred in patients treated with mobocertinib. Mobocertinib can cause QTc prolongation resulting in Torsades de Pointes. Atrial fibrillation (1.3%), ventricular tachycardia (0.3%), first degree atrioventricular block (0.7%), second degree atrioventricular block (0.3%), left bundle branch block (0.3%), supraventricular extrasystoles (0.3%) and ventricular extrasystoles (0.3%) also occurred in patients receiving mobocertinib. The causality of these events to mobocertinib has not been established. Conduct cardiac monitoring, including assessment of left ventricular ejection fraction at baseline and during treatment. Patients who develop signs and symptoms consistent with cardiac failure should be treated as clinically indicated. Withhold, reduce the dose, or permanently discontinue mobocertinib based on the severity. Diarrhea In clinical studies, most patients experienced mild to moderate diarrhea. Diarrhea can be severe or life threatening. The median time to first onset of diarrhea was five days but could occur as soon as 24 hours after administration of mobocertinib. Diarrhea is usually transient and had a median time to resolution of three days. Prolonged diarrhea may lead to dehydration or electrolyte imbalance, with or without renal impairment. Early and compliant diarrhea management such as prescribed anti-diarrheal medicinal products (e.g., loperamide), diet, adequate fluid intake (~2L clear liquids per day), and patient education is recommended. Instruct patients to have anti-diarrheal medicinal products (e.g., loperamide) readily available. Begin anti-diarrheal treatment at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. In mobocertinib clinical trials where loperamide was used as the antidiarrheal, the dosage regimen for loperamide was 4 mg at the first bout of diarrhea and then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours; daily dose of loperamide did not exceed 16 mg. If using loperamide as the antidiarrheal treatment, refer to loperamide product labeling for additional information. If diarrhea does not improve or additional signs or symptoms are reported, standard medical practice intervention, including other anti-diarrheal medications, are recommended. Antidiarrheal prophylaxis may be considered as needed. Monitor electrolytes and instruct patients to increase fluid and electrolyte intake as needed. No dose modification is necessary unless the patient does not tolerate mobocertinib or the symptoms recur, or the diarrhea doesn’t resolve with medical intervention. Interrupt mobocertinib and reduce subsequent doses if severe diarrhea occurs. Embryo-Fetal Toxicity Based on its mechanism of action and data from animal studies, mobocertinib can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with mobocertinib and for one month following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with mobocertinib and for one week following the final dose of mobocertinib. Takeda’s Commitment to Oncology At Takeda Oncology, we are united by our aspiration to cure cancer and motivated every day to work harder for patients with limited or ineffective treatment options. Our agile structure and deep in-house expertise are complemented by a network of partnerships that optimize our ability to research, develop and deliver transformative medicines to people living with cancer. Building on decades of leadership in oncology and a portfolio of approved medicines for hematologic cancers and solid tumors, we are advancing a cutting-edge pipeline focused on the power of innate immunity. With inspiration from patients and innovation from everywhere, our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so that more patients can benefit from – and have access to – innovative medicines. For more information, visit . About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit . Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Regulatory information This indication is approved in China under conditional approval. 1 Gan J, Fang W, Zhang L. Therapy of lung cancer in China: introducing the special collection. Therapeutic Advances in Medical Oncology. 2021;13. 2 Riess, Jonathan W. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. (18)30770-6/fulltext. Accessed September 28, 2022. 3 Fang, Wenfeng. BMC Cancer. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. . Accessed September 28, 2022. 4 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179-1186. doi:10.1111/cas.12996 5 Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438-445. doi:10.1097/JTO.0000000000000422 6 Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006. doi:10.1001/jama.2014.3741 7 Yang, Guangjian et al. “EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.” Lung cancer (Amsterdam, Netherlands) vol. 145 (2020): 186-194. 8 Zhou C. Lung cancer molecular epidemiology in China: recent trends. Transl Lung Cancer Res. 2014 Oct;3(5):270-9. doi: 10.3978/j.issn.2218-6751.2014.09.01 9 Sung H. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. . Accessed September 28, 2022 10 American Cancer Society. What is Non-Small Cell Lung Cancer? . Accessed September 28, 2022.

Atara Biotherapeutics – Amie Krause was named Senior Vice President and Chief People Officer at Atara Biotherapeutics. In this role, Krause will be tasked with building a company culture that “rewards” values through actions and results. Prior to her tenure with Atara, Krause held several HR leadership positions at Amgen, including her role as Global HR Lead, Organizational Effectiveness during which she served as the human resources lead for Amgen’s global commercial operations covering the Americas, Europe, Asia, and the Middle East. PsyBio Therapeutics – Michael Spigarelli was named chief medical officer of Ohio-based PsyBio. Before PsyBio Therapeutics, Spigarelli served as CMOr for Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases. Prior to that, he served as Vice President of Medical Affairs for Immucor, Inc., a leading provider of transfusion and transplantation diagnostic products worldwide. Spigarelli previously served as Chairman of the American Board of Clinical Pharmacology. Rune Labs – Bay Area-based Rune Labs announced the formation of a Scientific Advisory Board of leading experts in neuroscience and biomedical engineering. Carrolee Barlow and Srikantan Nagarajan were named members of the SAB. Barlow formerly served as Chief Executive Officer of the Parkinson's Institute and Clinical Center. Nagarajan is a Professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Umoja Biopharma – Nushmia Khokhar was named CMO of Seattle-based Umoja. Before Umoja, Khokhar was the Senior Vice President, Head of Clinical Development at Autolus where she played a critical role in advancing the company’s autologous T-cell products and clinical programs. Before that, she held numerous roles of increasing responsibility at Janssen Oncology. Prothena – Hideki Garren was named CMO of Ireland-based Prothena Corporation plc. Garren joins Prothena from Genentech, where he served as Vice President, Global Head of Neuroimmunology. Garren also held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Prior to Novartis, Garren served as Co-Founder, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc., a company he started in 2002 based on a technology platform he co-invented while at Stanford University. Vivasure Medical – Andrew Glass was tapped to serve as CEO of Ireland’s Vivasure Medical. Glass brings significant global experience in product development, clinical strategy and commercialization within the cardiovascular industry. Founder and former CEO Ger Brett will transition to serving as chief operating officer. Glass held senior leadership roles at Abbott Laboratories for the past fifteen years, most recently as regional director at Abbott Vascular where he was responsible for the commercial operations for 13 European countries. Previously, he served in senior leadership positions in general management, business development, and marketing in Europe, Asia-Pacific, and the United States. Overland ADCT – Overland ADCT Biopharma, a joint venture of Overland Pharmaceuticals and ADC Therapeutics SA, named Eric Koo as CEO. Koo most recently served as Vice President, Head of Oncology Business Unit at Takeda China with a focus on multiple myeloma and lymphoma. Prior to Takeda China, Koo served as Director, Oncology Business Unit and Director, Market Access, External Affairs & Key Account Management at Merck, Sharp and Dome (MSD) Taiwan. Prior to MSD, he served as Regional Marketing Director for APAC & Specialty Care BU Head, Malaysia/Singapore at Bayer APAC. Koo started his pharmaceutical career at Pfizer, spending 16 years in various sales, product management and marketing positions. Protera – Chile-based Protera appointed Novozymes senior executive Thomas Videbaek as chairman of the Board of Directors and non-executive board member. Most recently, Videbaek was Executive Vice President (EVP) of Corporate Strategy & Business Transformation at Novozymes. Previously, he held a number of senior business development roles, most recently as EVP. Cogent Biosciences – Boulder, Colo.-based Cogent Biosciences, Inc. announced the formation of a research team led by newly-appointed Chief Scientific Officer, John Robinson. Robinson joins Cogent from Pfizer where he most recently served as Vice President, Medicinal Chemistry. For more than 15 years prior to his time at Pfizer, he was a senior member of the Array BioPharma scientific leadership team. The Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions. Immuneering Corporation – Biren Amin was named chief financial officer of Immuneering. Amin joins Immuneering from Jefferies Financial Group Inc., where he served as Managing Director, Biotechnology Equity Research. LEXEO Therapeutics – New York-based LEXEO bolstered its executive team with two appointments. Paul McCormac was named Senior Vice President, Technical Operations and Libbie Mansell, was tapped as Senior Vice President and Head of Regulatory Affairs. McCormac previously served as Medicinal Sciences Category Lead for Pfizer Rare Disease, where he among other responsibilities led gene therapy CMC and vector supply strategy for Pfizer’s rare disease business and research units. Prior to Pfizer, he held positions in process development at Avecia Biotechnology. Mansell served as Senior Vice President, Regulatory Affairs at Asklepios Biopharmaceuticals. Prior to AskBio, Mansell held regulatory affairs or medical affairs leadership positions at Curis, Sigma-Tau, Genzyme and Millenium Pharmaceuticals among other companies. Olema Oncology – Yi Larson was appointed to the board of directors of Olema. Larson most recently served as CFO of Turning Point Therapeutics, where she oversaw a period of tremendous growth. Effective May 1, she will become CFO of LianBio. Prior to Turning Point, Larson was a Managing Director of Healthcare Investment Banking at Goldman Sachs. Longtime Olema director Frank McCormick will transition to Chair of Olema’s Scientific Advisory Board. NPC – John M. O’Brien was named president and CEO of the National Pharmaceutical Council, a health policy research organization. O'Brien, who will assume the role on June 1, will be responsible for overseeing NPC's policy research and communications capacity, partnerships with other health care organizations, and strategic vision. Prior to joining NPC, O'Brien was senior advisor to the U.S. Secretary of Health and Human Services and deputy assistant secretary of planning and evaluation (health policy). He has also held senior policy positions in the life sciences and managed care industries, including at CareFirst BlueCross BlueShield, was a career official at the Centers for Medicare & Medicaid Services during the Obama administration, and served as a health policy fellow in the U.S. Senate. O'Brien replaces interim president and CEO Robert Dubois, who took on the role after Dan Leonard left NPC in September 2020. Dubois will continue his role as CSO and executive vice president. Penrose TherapeuTx – Michigan-based Penrose named three new members to its SAB. The new members are: Mircea Ivan, a microbiologist and immunologist whose research contributed to the 2019 Nobel Prize in Medicine or Physiology for the discovery of how cells sense and adapt to oxygen availability; David Rubin, a gastroenterologist with expertise in high-risk cancer syndromes, inflammatory bowel diseases and clinical trial design; and Patrick Farmer, a chemical and biochemical expert whose research includes metal-based therapies for melanoma. SVB Leerink – Andrew Finberg was named Managing Director, He will be tasked with leading the firm’s new Structured Finance practice, which will advise corporate, academic, and medical not-for-profit clients on royalty monetization and private cash flow and asset-based credit. Fineberg joins SVB from MTS Health Partners where he led the structured finance advisory efforts, primarily focused on structuring and executing royalty monetization, debt financings, and other credit-based transactions. Exact Therapeutics – Biopharma veteran Dominic Moreland was named CFO of Exact Therapeutics. Moreland has held financial role in multiple life sciences companies, including ICI/Zeneca, Baxter, Genzyme, and two independent businesses, Careology and the Whiteley Clinic as well as Autolus Therapeutics plc. OneOncology – Eastern Connecticut Hematology and Oncology (ECHO)'s Dinesh Kapur, has succeeded Natalie Dickson, president and CMO of Tennessee Oncology as chair of OneCouncil, the partnership's all-physician advisory board for clinical and strategic initiatives. Click Therapeutics – New York-based Click Therapeutics expands its leadership team with executive and board appointments. Wall Street veteran Randall Stanicky joined the company leadership as CFO; digital healthcare executive Lee Shapiro joined the Board of Directors; and former biopharmaceutical executive Muzammil Mansuri, has expanded his role at Click through appointment as Board Chair Medable Inc. – Pamela Tenaerts was named CSO of California-based Medable. Tenaerts joins Medable from Duke University, where she led CTTI’s efforts to develop and drive adoption of practices that increase the quality and efficiency of clinical trials. CTTI is a public-private partnership co-founded in 2007 by Duke and the U.S. Food and Drug Administration. It comprises more than 80 member organizations, including government agencies, industry representatives, patient advocacy groups, professional societies, investigator groups, and academic institutions. Rain Therapeutics – Richard Bryce was named CMO of Rain Therapeutics. Bryce joins Rain from Puma Biotechnology, where he served as chief medical and scientific officer since 2017. Prior to Puma, he served as the senior medical director of clinical science at Onyx Pharmaceuticals. Before Onyx, Bryce was the senior director of medical affairs and oncology at ICON Clinical Research and spent time at Ergomed Clinical Research serving as executive vice president of medical affairs, president and managing director. Earlier in his career, he held senior clinical and medical roles at F. Hoffmann-La Roche, ILEX Oncology, Scotia Pharmaceuticals and Servier Laboratories.